Yahoo Finance

Featured Company News - IMRALDI(R), Biogen's Version of AbbVie's Humira(R), Approved in the European Union

LONDON, UK / ACCESSWIRE / August 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Biogen Inc. (NASDAQ: BIIB), following which we have published ...
Medscape

CHMP Recommends Imraldi, a Biosimilar to Humira

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has voted to recommend marketing authorization for Imraldi (adalimumab, Samsung Bioepsis UK Limited) ...
MedPage Today

Humira Biosimilars Found to Be as Effective as the Original

Amjevita and Imraldi, two biosimilar agents for adalimumab (Humira), were just as effective in treating psoriasis as the original drug for both new users and patients who switched from adalimumab to ...
Healio

EMA recommends approval of Humira biosimilar Imraldi

Please provide your email address to receive an email when new articles are posted on . The European Medicines Agency has recommended the approval of the Imraldi, making it the third anti-TNF ...
Business Insider

IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union

BAAR, Switzerland, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Samsung Bioepis Co. Ltd, a joint venture between Samsung BioLogics and Biogen (Nasdaq: BIIB) today announced the European launch of IMRALDI TM, an ...
Business Wire

Samsung Bioepis First to Obtain European Commission Approval for a Third Anti-TNF-α Biosimilar with Imraldi ® (adalimumab)

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Imraldi ®, a biosimilar referencing Humira ® 1 (adalimumab), for the treatment of ...
Nasdaq

Biogen's Humira Biosimilar Imraldi Gets Approval in EU

Biogen Inc.BIIB announced that its biosimilar version of AbbVie, Inc.'s ABBV top-selling blockbuster drug, Humira has been approved by the European Commission. The biosimilar will be marketed by the ...
elEconomista

Biogen´s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use

If approved by the EC, IMRALDI would be approved for the treatment of rheumatoid arthritis, axial spondyloarthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, Crohn´s disease, ...
중앙일보

Bioepis’ Imraldi biosimilar set to reach Europe by October

Korean biopharmaceutical firm Samsung Bioepis said Friday its biosimilar Imraldi is set to reach the European market in October following the settling of a patent dispute with the drug’s original ...
MedPage Today

Humira Copycats for Psoriasis Backed by Real-World Outcomes

Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...
Finanznachrichten

IMRALDI, Biogen's Adalimumab Biosimilar Referencing Humira, is Approved in the European Union

IMRALDI has been developed by Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen (NASDAQ, BIIB) and is approved for the treatment of rheumatoid arthritis (RA), juvenile idiopathic ...
Finanznachrichten

Biogen Inc.: IMRALDI, Biogen's Adalimumab Biosimilar Referencing Humira, Is Launched in the European Union

The launch of IMRALDI completes Biogen's portfolio of three anti-TNF biosimilars in Europe, with BENEPALI TM (etanercept), a biosimilar referencing Enbrel 2, and FLIXABI TM (infliximab), a biosimilar ...